JP2021072840A5 - - Google Patents

Download PDF

Info

Publication number
JP2021072840A5
JP2021072840A5 JP2021014429A JP2021014429A JP2021072840A5 JP 2021072840 A5 JP2021072840 A5 JP 2021072840A5 JP 2021014429 A JP2021014429 A JP 2021014429A JP 2021014429 A JP2021014429 A JP 2021014429A JP 2021072840 A5 JP2021072840 A5 JP 2021072840A5
Authority
JP
Japan
Prior art keywords
tds
mcds
adds
nucleoside bond
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021014429A
Other languages
English (en)
Other versions
JP7198298B2 (ja
JP2021072840A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021072840A publication Critical patent/JP2021072840A/ja
Publication of JP2021072840A5 publication Critical patent/JP2021072840A5/ja
Priority to JP2022200959A priority Critical patent/JP2023027299A/ja
Application granted granted Critical
Publication of JP7198298B2 publication Critical patent/JP7198298B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (35)

  1. 12個〜30個の連結されたヌクレオシドからなりかつ配列番号118〜724および726〜1461の核酸塩基配列のいずれかの少なくとも8個、少なくとも9個、少なくとも10個、少なくとも11個、少なくとも12個、少なくとも13個、少なくとも14個、少なくとも15個、少なくとも16個、少なくとも17個、少なくとも18個、少なくとも19個、または少なくとも20個の連続する核酸塩基を含む核酸塩基配列を有する修飾オリゴヌクレオチド、を含む化合物。
  2. 前記修飾オリゴヌクレオチドが混成バックボーンを有する、請求項1に記載の化合物。
  3. 前記混成バックボーンモチーフが以下から選択される、請求項2に記載の化合物:
    sossssssssoooss、
    sooossssssssoss、
    sooosssssssssoss、
    soosssssssssooss、
    sooossssssssooss、
    sooosssssssssooss、
    sooossssssssssooss、
    sooosssssssssssooos、
    soooossssssssssooss、
    sooosssssssssssooss、
    sososssssssssssosos、及び
    sooossssssssssoooss
    (式中、s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  4. 前記修飾オリゴヌクレオチドが以下のいずれかの糖化学モチーフを有する、請求項1〜3のいずれか1つに記載の化合物:
    abddddddddababaa、
    babaddddddddabab、
    aaaadddddddddbbaa、
    aaaaddddddddababa、
    aaaaddddddddbabaa、
    aaaaddddddddbbaaa、
    aaaaaddddddddbbaa、
    aaaabddddddddbaaa、
    aaaabdddddddbaaaa、
    aaabddddddddbaaaa、
    aaabbdddddddbbaaa、
    aabbdddddddddbbaa、
    aabbddddddddaaaaa、
    aabbddddddddbbaaa、
    ababddddddddaaaaa、
    ababddddddddbabaa、及び
    babaddddddddaaaaa
    (式中、e=任意の2’非二環式修飾糖、
    b=任意の二環式修飾糖、
    d=2’−デオキシリボース糖)。
  5. 前記修飾オリゴヌクレオチドが以下のいずれかの糖化学モチーフを有する、請求項4に記載の化合物:
    ekddddddddekekee、
    kekeddddddddekek、
    eeeedddddddddkkee、
    eeeeddddddddekeke、
    eeeeddddddddkekee、
    eeeeddddddddkkeee、
    eeeeeddddddddkkee、
    eeeekddddddddkeee、
    eeeekdddddddkeeee、
    eeekddddddddkeeee、
    eeekkdddddddkkeee、
    eekkdddddddddkkee、
    eekkddddddddeeeee、
    eekkddddddddkkeee、
    ekekddddddddeeeee、
    ekekddddddddkekee、及び
    kekeddddddddeeeee
    (式中、e=2’−O−メトキシエチルリボース修飾糖、
    k=cEt修飾糖、
    d=2’−デオキシリボース糖)。
  6. 少なくとも1つのヌクレオシド間結合がホスホロチオエート結合であり、かつ少なくとも1つのヌクレオシド間結合がホスホジエステル結合である、請求項1、4または5に記載の化合物。
  7. 以下の式に従う修飾オリゴヌクレオチドからなる化合物:
    Figure 2021072840
  8. 以下の式に従う修飾オリゴヌクレオチドからなる化合物:
    Figure 2021072840
  9. 以下の式に従う修飾オリゴヌクレオチドからなる化合物:
    Figure 2021072840
  10. 以下の式に従う修飾オリゴヌクレオチドからなる化合物:
    Figure 2021072840
  11. 以下の式に従う修飾オリゴヌクレオチドからなる化合物:
    Figure 2021072840
  12. 以下の式に従う修飾オリゴヌクレオチドからなる化合物:
    Figure 2021072840
  13. 以下の式に従う修飾オリゴヌクレオチドからなる化合物:
    Figure 2021072840
  14. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Tes Teo Aeo Aes Tds Gds Tds Tds Tds Ads Tds mCds Ako Gko Ges Aes Te
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    k=cEt修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  15. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Ges Geo Aeo Teo Ads mCds Ads Tds Tds Tds mCds Tds Ads mCko Aks Ges mCe
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    k=cEt修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  16. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Ges Geo Aeo Teo Aes mCds Ads Tds Tds Tds mCds Tds Ads mCko Aks Ges mCe
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    k=cEt修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  17. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Ges Geo Aeo Teo Aks mCds Ads Tds Tds Tds mCds Tds Ads mCko Aes Ges mCe
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    k=cEt修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  18. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Aes Gko Teo Gks Tds Tds Tds Ads Ads Tds Gds Tds Tko Teo Aks Tes mCe
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    k=cEt修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  19. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Aes Gko Teo Gks Tds Tds Tds Ads Ads Tds Gds Tds Teo Teo Aes Tes mCe
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    k=cEt修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  20. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Aes Geo Tko Gks Tds Tds Tds Ads Ads Tds Gds Tds Teo Teo Aes Tes mCe
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    k=cEt修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  21. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    mCes mCeo Geo Teo mCeo Gds mCds mCds mCds Tds Tds mCds Ads Gds mCds Aeo mCeo Ges mCes Ae
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  22. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    mCes mCeo Geo Teo mCes Gds mCds mCds mCds Tds Tds mCds Ads Ges mCeo Aeo mCeo Ges mCes Ae
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  23. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    mCes mCeo Geo Teo mCes Gds mCds mCds mCds Tds Tds mCds Ads Gds mCds Aeo mCeo Geo mCes Ae
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  24. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Aes mCeo Aeo mCeo mCes Tds Tds mCds Ads mCds Tds Gds Gds Tds mCds mCeo Aeo Teo Tes Ae
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  25. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Ges Geo mCeo Geo Aes Tds mCds mCds mCds Ads Ads Tds Tds Ads mCds Aeo mCeo mCeo Aes mCe
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  26. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Ges Geo mCeo Geo Aes Tes mCds mCds mCds Ads Ads Tds Tds Ads mCeo Aeo mCeo mCes Aes mCe
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  27. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Ges Geo mCeo Geo Aes Tds mCds mCds mCds Ads Ads Tds Tds Aes mCeo Aeo mCeo mCes Aes mCe
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  28. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Ges Geo mCeo Geo Aeo Tes mCds mCds mCds Ads Ads Tds Tds Ads mCds Aeo mCeo mCes Aes mCe
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  29. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Ges Teo mCeo Geo mCes mCds mCds Tds Tds mCds Ads Gds mCds Ads mCds Geo mCeo Aeo mCes Ae
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  30. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Tes mCeo Geo mCeo mCes mCds Tds Tds mCds Ads Gds mCds Ads mCds Gds mCeo Aeo mCeo Aes mCe
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    d=2’−デオキシリボース糖、
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)。
  31. 以下の式に従う修飾オリゴヌクレオチドを含む化合物:
    Ges Aes Aes Aes Tes Tds Gds Ads Tds Gds Ads Tds Gds mCds mCds mCes Tes Ges mCes Ae
    (式中、A=アデニン、
    mC=5−メチルシトシン
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    d=2’−デオキシリボース糖、及び
    s=ホスホロチオエートヌクレオシド間結合)。
  32. SOD−1に関連する神経変性疾患を処置するための医薬組成物であって、請求項1〜31のいずれか1項に記載の化合物を含む、前記医薬組成物。
  33. SOD−1に関連する筋萎縮性側索硬化症を処置するための医薬組成物であって、請求項1〜31のいずれか1項に記載の化合物を含む、前記医薬組成物。
  34. ヒト対象における家族性筋萎縮性側索硬化症(ALS)を処置または予防するための医薬組成物であって、以下の式のアンチセンス化合物またはその薬理学的に許容される塩:
    mCes Aeo Ges Geo Aes Tds Ads mCds Ads Tds Tds Tds mCds Tds Ads mCeo Aes Geo mCes Te (配列番号725の核酸塩基配列)
    (式中、
    A=アデニン、
    mC=5−メチルシトシン、
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    d=2’−デオキシリボース糖
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)
    を含む医薬組成物。
  35. ヒト対象における孤発性筋萎縮性側索硬化症(ALS)を処置または予防するための医薬組成物であって、以下の式のアンチセンス化合物またはその薬理学的に許容される塩:
    mCes Aeo Ges Geo Aes Tds Ads mCds Ads Tds Tds Tds mCds Tds Ads mCeo Aes Geo mCes Te (配列番号725の核酸塩基配列)
    (式中、
    A=アデニン、
    mC=5−メチルシトシン、
    G=グアニン、
    T=チミン、
    e=2’−O−メトキシエチルリボース修飾糖、
    d=2’−デオキシリボース糖
    s=ホスホロチオエートヌクレオシド間結合、及び
    o=ホスホジエステルヌクレオシド間結合)
    を含む医薬組成物。
JP2021014429A 2014-04-01 2021-02-01 Sod-1発現を調節するための組成物 Active JP7198298B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022200959A JP2023027299A (ja) 2014-04-01 2022-12-16 Sod-1発現を調節するための組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973803P 2014-04-01 2014-04-01
US61/973,803 2014-04-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019141933A Division JP2019201664A (ja) 2014-04-01 2019-08-01 Sod−1発現を調節するための組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022200959A Division JP2023027299A (ja) 2014-04-01 2022-12-16 Sod-1発現を調節するための組成物

Publications (3)

Publication Number Publication Date
JP2021072840A JP2021072840A (ja) 2021-05-13
JP2021072840A5 true JP2021072840A5 (ja) 2021-07-29
JP7198298B2 JP7198298B2 (ja) 2022-12-28

Family

ID=54241435

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016560543A Active JP6622214B2 (ja) 2014-04-01 2015-04-01 Sod−1発現を調節するための組成物
JP2019141933A Withdrawn JP2019201664A (ja) 2014-04-01 2019-08-01 Sod−1発現を調節するための組成物
JP2021014429A Active JP7198298B2 (ja) 2014-04-01 2021-02-01 Sod-1発現を調節するための組成物
JP2022200959A Pending JP2023027299A (ja) 2014-04-01 2022-12-16 Sod-1発現を調節するための組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016560543A Active JP6622214B2 (ja) 2014-04-01 2015-04-01 Sod−1発現を調節するための組成物
JP2019141933A Withdrawn JP2019201664A (ja) 2014-04-01 2019-08-01 Sod−1発現を調節するための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022200959A Pending JP2023027299A (ja) 2014-04-01 2022-12-16 Sod-1発現を調節するための組成物

Country Status (26)

Country Link
US (3) US10385341B2 (ja)
EP (3) EP3126499B1 (ja)
JP (4) JP6622214B2 (ja)
KR (4) KR20230085222A (ja)
CN (2) CN111440798A (ja)
AU (3) AU2015240761B2 (ja)
BR (1) BR112016021848B1 (ja)
CA (1) CA2942394A1 (ja)
CL (3) CL2016002509A1 (ja)
CY (1) CY1123288T1 (ja)
DK (2) DK3757214T3 (ja)
ES (2) ES2926869T3 (ja)
HR (2) HRP20220798T1 (ja)
HU (2) HUE050704T2 (ja)
IL (2) IL247714B (ja)
LT (2) LT3757214T (ja)
MX (2) MX2016012922A (ja)
MY (2) MY175665A (ja)
NZ (1) NZ724100A (ja)
PL (2) PL3757214T3 (ja)
PT (2) PT3126499T (ja)
RS (2) RS60707B1 (ja)
RU (1) RU2704619C2 (ja)
SG (3) SG10201910844SA (ja)
SI (2) SI3757214T1 (ja)
WO (1) WO2015153800A2 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60707B1 (sr) * 2014-04-01 2020-09-30 Biogen Ma Inc Kompozicije za modulaciju ekspresije sod-1
US10590420B2 (en) * 2014-07-31 2020-03-17 Association Institut De Myologie Treatment of amyotrophic lateral sclerosis
CA2975583A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Modulatory polynucleotides
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
CA3024448A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Modulatory polynucleotides
WO2017218454A1 (en) 2016-06-14 2017-12-21 Biogen Ma Inc. Hydrophobic interaction chromatography for purification of oligonucleotides
JP7235512B2 (ja) 2016-06-24 2023-03-08 バイオジェン・エムエイ・インコーポレイテッド キャッピング工程を有さないチオール化オリゴヌクレオチドの合成
AU2018261790A1 (en) 2017-05-05 2019-11-28 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
EP3631470A4 (en) * 2017-05-26 2021-03-24 University of Miami DETERMINATION OF THE ONSET OF AMYOTROPHIC LATERAL SCLEROSIS
EP3697905A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
JP2021511389A (ja) 2018-01-25 2021-05-06 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 脊髄性筋萎縮症を治療する方法
PE20210518A1 (es) 2018-06-27 2021-03-17 Ionis Pharmaceuticals Inc Compuestos y metodos para la reduccion de la expresion de lrrk2
JP7455831B2 (ja) 2018-11-21 2024-03-26 アイオーニス ファーマシューティカルズ, インコーポレーテッド プリオン発現を低減するための化合物及び方法
BR112021010660A2 (pt) * 2018-12-06 2021-08-24 Biogen Ma Inc. Proteína de neurofilamento para guiar intervenção terapêutica sobre esclerose lateral amiotrófica
TW202035694A (zh) * 2018-12-14 2020-10-01 美商百健Ma公司 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法
CN114206352A (zh) * 2019-03-26 2022-03-18 罗格斯新泽西州立大学 用于治疗神经变性障碍的组合物和方法
AU2020264807A1 (en) * 2019-05-01 2021-11-18 Black Swan Pharmaceuticals, Inc. Treatment for SOD1 associated disease
WO2020227395A2 (en) * 2019-05-06 2020-11-12 University Of Massachusetts Anti-c9orf72 oligonucleotides and related methods
AU2020268415A1 (en) 2019-05-08 2021-12-23 Biogen Ma Inc. Convergent liquid phase syntheses of oligonucleotides
EP3976791A4 (en) * 2019-05-28 2023-10-11 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR REDUCING FOOT EXPRESSION
IL304880A (en) 2021-02-12 2023-10-01 Alnylam Pharmaceuticals Inc Superoxide dismutase 1 (SOD1) IRNA compositions and methods of using them to treat or prevent superoxide dismutase 1- (SOD1-) associated neurodegenerative diseases
KR20230172502A (ko) 2021-03-31 2023-12-22 바이오젠 엠에이 인코포레이티드 근위축성 측삭경화증의 치료
CN117337168A (zh) 2021-04-01 2024-01-02 渤健马萨诸塞州股份有限公司 向中枢神经系统的核酸递送
CN114369130B (zh) * 2021-12-28 2023-10-03 杭州天龙药业有限公司 修饰的硫代寡核苷酸及其应用
WO2023245060A2 (en) * 2022-06-15 2023-12-21 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use
KR20240038469A (ko) 2022-09-16 2024-03-25 김정훈 사용자 콘텐츠 기반 홍보 서비스 제공 장치 및 방법

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
DE3329892A1 (de) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
USRE34036E (en) 1984-06-06 1992-08-18 National Research Development Corporation Data transmission using a transparent tone-in band system
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
EP0260032B1 (en) 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
JP2828642B2 (ja) 1987-06-24 1998-11-25 ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン ヌクレオシド誘導体
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
ATE151467T1 (de) 1987-11-30 1997-04-15 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
WO1989009221A1 (en) 1988-03-25 1989-10-05 University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
WO1990005181A1 (de) 1988-11-07 1990-05-17 Cl-Pharma Aktiengesellschaft REINIGUNG VON Cu/Zn-SUPEROXIDDISMUTASE
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
AU658562B2 (en) 1989-10-24 1995-04-27 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5623065A (en) 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5536638A (en) 1990-04-18 1996-07-16 N.V. Innogenetics S.A. Hybridization probes derived from the spacer region between the 16S and 23S rRNA genes for the detection of Neisseria gonorrhoeae
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ATE167523T1 (de) 1990-05-11 1998-07-15 Microprobe Corp Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
CA2088258C (en) 1990-07-27 2004-09-14 Phillip Dan Cook Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
ATE131827T1 (de) 1990-08-03 1996-01-15 Sterling Winthrop Inc Verbindungen und verfahren zur unterdrückung der genexpression
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
EP0549686A4 (en) 1990-09-20 1995-01-18 Gilead Sciences Inc Modified internucleoside linkages
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5948903A (en) 1991-01-11 1999-09-07 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
EP0538194B1 (de) 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
DE637965T1 (de) 1991-11-26 1995-12-14 Gilead Sciences Inc Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen.
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US6784290B1 (en) 1992-10-05 2004-08-31 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
WO1994014226A1 (en) 1992-12-14 1994-06-23 Honeywell Inc. Motor system with individually controlled redundant windings
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5843641A (en) 1993-02-26 1998-12-01 Massachusetts Institute Of Technology Methods for the daignosis, of familial amyotrophic lateral sclerosis
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
GB9304620D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Compounds
JPH08508492A (ja) 1993-03-30 1996-09-10 スターリング ウィンスロップ インコーポレイティド 非環式ヌクレオシド類似体及びそれらを含むオリゴヌクレオチド配列
HU9501974D0 (en) 1993-03-31 1995-09-28 Sterling Winthrop Inc Oligonucleotides with amide linkages replacing phosphodiester linkages
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
EP0733059B1 (en) 1993-12-09 2000-09-13 Thomas Jefferson University Compounds and methods for site-directed mutations in eukaryotic cells
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5877021A (en) 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
EP0862439A4 (en) 1995-11-22 2001-01-10 O Paul O P Ts LIGANDS FOR INCREASING THE CELLULAR UPtake OF BIOMOLECULES
DE69637256T2 (de) 1996-01-16 2008-06-19 Sirna Therapeutics, Inc., Boulder Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
WO1997031012A1 (en) 1996-02-22 1997-08-28 The Regents Of The University Of Michigan Gene specific universal mammalian sequence-tagged sites
US6077833A (en) 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6352829B1 (en) 1997-05-21 2002-03-05 Clontech Laboratories, Inc. Methods of assaying differential expression
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
TR200604211T1 (tr) 1999-02-12 2007-02-21 Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited Yeni nükleosid ve oligonükleotid analoglarıYeni nükleosid ve oligonükleotid analogları
US5998148A (en) 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
EP1178999B1 (en) 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US9029523B2 (en) 2000-04-26 2015-05-12 Ceres, Inc. Promoter, promoter control elements, and combinations, and uses thereof
JP4151751B2 (ja) 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
ES2261270T3 (es) 1999-12-30 2006-11-16 K.U. LEUVEN RESEARCH & DEVELOPMENT Acidos nucleicos que contienen ciclohexeno.
US6303374B1 (en) 2000-01-18 2001-10-16 Isis Pharmaceuticals Inc. Antisense modulation of caspase 3 expression
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
AU2001250572A1 (en) 2000-04-07 2001-10-23 Epigenomics Ag Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
US20020106348A1 (en) 2000-07-12 2002-08-08 Peng Huang Cancer therapeutics involving the administration of 2-methoxyestradiol and an agent that increases intracellular superoxide anion
US7053199B2 (en) 2000-08-29 2006-05-30 Takeshi Imanishi Nucleoside analogs and oligonucleotide derivatives containing these analogs
IL155450A0 (en) 2000-10-20 2003-11-23 Expression Diagnostics Inc Leukocyte expression profiling
US6426220B1 (en) 2000-10-30 2002-07-30 Isis Pharmaceuticals, Inc. Antisense modulation of calreticulin expression
WO2002040498A2 (en) 2000-11-14 2002-05-23 University Of Iowa Research Foundation Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides
WO2002043771A2 (en) 2000-12-01 2002-06-06 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide
WO2002044321A2 (en) 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
EP2221376B1 (en) 2001-06-21 2012-11-21 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
US20030158403A1 (en) 2001-07-03 2003-08-21 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US20030175906A1 (en) 2001-07-03 2003-09-18 Muthiah Manoharan Nuclease resistant chimeric oligonucleotides
EP1499627A2 (en) 2001-07-03 2005-01-26 ISIS Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US7060809B2 (en) 2001-09-04 2006-06-13 Exiqon A/S LNA compositions and uses thereof
JP2003319198A (ja) 2002-04-19 2003-11-07 Orion Denki Kk X線プロテクタ装置
AU2003290586B2 (en) * 2002-11-04 2009-07-02 University Of Massachusetts Allele-specific RNA interference
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004044136A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2’-modified nucleosides for use in gene modulation
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
PT2284266E (pt) 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Siarn contra tp53
US7655785B1 (en) 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7888497B2 (en) 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
WO2005027962A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
US20050118625A1 (en) 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
AU2005252662B2 (en) 2004-06-03 2011-08-18 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US20080261905A1 (en) 2004-11-08 2008-10-23 K.U. Leuven Research And Development Modified Nucleosides for Rna Interference
WO2006066203A2 (en) * 2004-12-16 2006-06-22 Alsgen, Llc Small interfering rna (sirna) molecules for modulating superoxide dismutase (sod)
US20060148740A1 (en) 2005-01-05 2006-07-06 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
CA2637678A1 (en) * 2006-01-26 2007-08-09 University Of Massachusetts Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
AU2007211080B9 (en) 2006-01-27 2012-05-03 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
EP3202905A1 (en) 2006-10-18 2017-08-09 Ionis Pharmaceuticals, Inc. Antisense compounds
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US8278426B2 (en) 2007-06-08 2012-10-02 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
ATE538127T1 (de) 2007-07-05 2012-01-15 Isis Pharmaceuticals Inc 6-disubstituierte bicyclische nukleinsäureanaloga
AU2008286771B2 (en) 2007-08-15 2013-08-15 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US20090130195A1 (en) 2007-10-17 2009-05-21 Mildred Acevedo-Duncan Prostate carcinogenesis predictor
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
EP2231195B1 (en) 2007-12-04 2017-03-29 Arbutus Biopharma Corporation Targeting lipids
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
CN102016036B (zh) 2008-02-11 2015-04-08 阿克赛医药公司 经修饰的RNAi多核苷酸及其用途
WO2009126933A2 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
DK2361256T3 (da) 2008-09-24 2013-07-01 Isis Pharmaceuticals Inc Cyclohexenyl-nukleinsyreanaloger
EP2356129B1 (en) 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US9102938B2 (en) 2010-04-01 2015-08-11 Alnylam Pharmaceuticals, Inc. 2′ and 5′ modified monomers and oligonucleotides
WO2011127307A1 (en) 2010-04-07 2011-10-13 Isis Pharmaceuticals, Inc. Modulation of cetp expression
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133871A2 (en) * 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
US9290760B2 (en) 2010-09-15 2016-03-22 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
EP3467109A1 (en) 2011-02-08 2019-04-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
CR20190207A (es) 2011-04-21 2019-06-26 Ionis Pharmaceuticals Inc MODULACIÓN DE LA EXPRESIÓN DEL VIRUS DE LA HEPATITIS B (VHB) (Divisional 2013-0551)
WO2013033230A1 (en) 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
US9914922B2 (en) 2012-04-20 2018-03-13 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
JP2016522674A (ja) 2012-05-16 2016-08-04 ラナ セラピューティクス インコーポレイテッド 遺伝子発現を調節するための組成物及び方法
WO2014059353A2 (en) 2012-10-11 2014-04-17 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and uses thereof
RU2653438C2 (ru) 2012-11-15 2018-05-08 Рош Инновейшен Сентер Копенгаген А/С Конъюгаты олигонуклеотидов
PE20152002A1 (es) 2013-05-01 2016-01-21 Isis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de ttr y vhb
FI3702466T3 (fi) 2013-08-27 2023-03-23 Res Inst Nationwide Childrens Hospital Valmisteita ja menetelmiä amyotrofisen lateraaliskleroosin hoitoon
US9344563B2 (en) 2013-09-19 2016-05-17 Verizon Patent And Licensing Inc. System for and method of recycling numbers seamlessly
RS60707B1 (sr) 2014-04-01 2020-09-30 Biogen Ma Inc Kompozicije za modulaciju ekspresije sod-1
ES2849600T3 (es) * 2014-05-01 2021-08-19 Ionis Pharmaceuticals Inc Conjugados de oligonucleótidos antisentido modificados y su uso para modular la expresión de PKK
US10590420B2 (en) 2014-07-31 2020-03-17 Association Institut De Myologie Treatment of amyotrophic lateral sclerosis
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
JP6983752B2 (ja) 2015-07-06 2021-12-17 フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. スーパーオキシドディスムターゼ1(sod1)を標的とする核酸分子
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
AU2018261790A1 (en) 2017-05-05 2019-11-28 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
TW202020154A (zh) * 2018-07-25 2020-06-01 美商Ionis製藥公司 用於減少atxn2表現之化合物及方法

Similar Documents

Publication Publication Date Title
JP2021072840A5 (ja)
JP2017513469A5 (ja)
AU682576B2 (en) Nucleosides and oligonucleotides having 2'-ether groups
AU2020203825B2 (en) Antisense-induced exon2 inclusion in acid alpha-glucosidase
JP2020193199A5 (ja)
JP2018525030A5 (ja)
KR102071729B1 (ko) 안티센스 핵산
Hildbrand et al. 5-Substituted 2-aminopyridine C-nucleosides as protonated cytidine equivalents: increasing efficiency and selectivity in DNA triple-helix formation
JP2020022483A5 (ja)
TWI725990B (zh) 反義核酸
JP2020072732A5 (ja)
JPH072889A (ja) 2’−エーテル基を有するヌクレオシド及びオリゴヌクレオチド
TW202208625A (zh) 經修飾之短干擾核酸(siNA)分子及其用途
HUT65941A (en) Backbone modified oligonucleotide analogues and pharmaceutical preparations containing them
JPH08508492A (ja) 非環式ヌクレオシド類似体及びそれらを含むオリゴヌクレオチド配列
JPH083186A (ja) 修飾オリゴヌクレオチド、その調製およびその使用
JP2020533009A (ja) GalNAc誘導体
WO2019182037A1 (ja) 毒性が低減されたアンチセンスオリゴヌクレオチド
KR20190047025A (ko) 변형된 올리고뉴클레오티드 및 사용 방법
JP2024041845A (ja) ホスホロジチオアートヌクレオシド間結合を含むギャップマーオリゴヌクレオチド
EP3207135A2 (en) Isotopologues of smad7 antisense oligonucleotides
JP2023139252A (ja) 新規のチオホスホラミダイト
JPWO2020006267A5 (ja)
WO2019175260A2 (en) Modified oligonucleotides and methods of use in tauopathies
JP2018518167A5 (ja)